| Liu, Jie |
NCT06082180: A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer |
|
|
| Recruiting | 3 | 1199 | RoW | prophylactic central neck dissection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Thyroid Cancer, Recurrence | 06/25 | 12/26 | | |
NCT05243355: Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC |
|
|
| Recruiting | 2 | 46 | RoW | "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin" | Qilu Hospital of Shandong University | Squamous Non-small Cell Lung Cancer | 12/23 | 12/24 | | |
NCT06087068: Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma |
|
|
| Recruiting | 2 | 140 | RoW | Thyroxine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Thyroid Cancer, Surgery, Recurrence | 07/26 | 12/26 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT04479553: Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study. |
|
|
| Recruiting | N/A | 30000 | RoW | Qizhi Tongluo Capsules | Zhong Wang, Shanxi Zhendong Pharmacy Co., Ltd | Safety Surveillance, Adverse Drug Events, Adverse Drug Reactions, Severe Adverse Events, Severe Adverse Reactions | 09/23 | 12/23 | | |
EMPACT-Us, NCT05750537: Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients |
|
|
| Recruiting | N/A | 13496 | US | EMPACT-Us | Family Health Centers of San Diego, University of California, San Diego, Tobacco Related Disease Research Program | Tobacco Use Cessation | 06/25 | 06/25 | | |
LIGHT-MCI, NCT05313529: Evaluating the Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Patients With Type 2 Diabetes: a Multi-center, Randomized, Parallel Controlled Clinical Trial With an Extension Phase |
|
|
| Recruiting | N/A | 396 | RoW | Liraglutide, metformin, Empagliflozin, Linagliptin | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing First Hospital, Nanjing Medical University, The Affiliated Jiangning Hospital of Nanjing Medical University, Wuxi People's Hospital, Changzhou No.2 People's Hospital | Type 2 Diabetes Mellitus, Mild Cognitive Impairment | 12/26 | 12/27 | | |
| Jiang, Hongwei |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
UplighTED, NCT06307613: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease |
|
|
| Recruiting | 3 | 108 | Europe, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) |
|
|
| Completed | 3 | 168 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes | 10/24 | 10/24 | | |
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor |
|
|
| Recruiting | 3 | 520 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 06/25 | 06/25 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 405 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteo Arthritis Knee | 02/26 | 03/26 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
| Ma, Yujin |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
| Li, Liping |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® |
|
|
| Not yet recruiting | 3 | 370 | RoW | Semaglutide | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Obesity | 05/26 | 10/26 | | |
NCT05391776: TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density |
|
|
| Recruiting | 1 | 32 | RoW | TST002 Injection, TST002-IgG4, placebo | HJB (Hangzhou) Co., Ltd. | Osteoporosis | 04/23 | 06/23 | | |
NCT04596072: A Clinical Trail of Acupuncture and Herbs for Post-stroke Cogntive Impairment |
|
|
| Recruiting | N/A | 123 | RoW | Chinese traditional rehabilitation | The Third Affiliated hospital of Zhejiang Chinese Medical University | Post-stroke Cognitive Impairment | 05/23 | 12/23 | | |
NCT04398355: A Clinical Trail of Acupuncture and Liu-Zi-Jue Exercise for Dysphagia in Post-stroke |
|
|
| Recruiting | N/A | 240 | RoW | acupuncture, Liu-Zi-Jue Gongfa | The Third Affiliated hospital of Zhejiang Chinese Medical University | Stroke | 12/23 | 12/23 | | |
